Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Jewett

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
Prostate Cancer|June 27, 2022
Expansion of Lymphocytes from Prostatic Adenocarcinoma and Adjacent Nonmalignant TissueLinh T Nguyen, Charlotte S Lo, Michael Fyrsta, et al.
BJU International|November 13, 2010
Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional studyCarmen Mir, Shahrokh F Shariat, Theodorus H van der Kwast, et al.
BJU International|October 27, 2021
Cytoreductive nephrectomy and exposure to sunitinib - a post hoc analysis of the Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer (SURTIME) trialYasmin Abu-Ghanem, Johannes V van Thienen, Christian Blank, et al.
JAMA Oncology|December 14, 2018
Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical TrialAxel Bex, Peter Mulders, Michael Jewett, et al.
Plos One|August 30, 2014
Cell surface profiling using high-throughput flow cytometry: a platform for biomarker discovery and analysis of cellular heterogeneityCraig A Gedye, Ali Hussain, Joshua Paterson, et al.
The Journal of Urology|October 29, 2024
Long-Term Recurrence Risk, Metastatic Potential, and Length of Cystoscopic Surveillance of Low-Grade Nonmuscle-Invasive Bladder CancerEunice Villegas, Katherine Lajkosz, Shayan Din, et al.
Urologic Oncology|January 10, 2017
Quality indicators in the management of bladder cancer: A modified Delphi studySatya R Khare, Armen Aprikian, Peter Black, et al.
Lancet (London, England)|March 13, 2016
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trialNaomi B Haas, Judith Manola, Robert G Uzzo, et al.
European Urology|January 24, 2025
A Call for a Neoadjuvant Kidney Cancer Consortium: Lessons Learned from Other Cancer TypesAxel Bex, Michael Jewett, Bryan Lewis, et al.
European Urology|January 15, 2008
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part IISusanne Krege, Jörg Beyer, Rainer Souchon, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
Prostate Cancer|June 27, 2022
Expansion of Lymphocytes from Prostatic Adenocarcinoma and Adjacent Nonmalignant TissueLinh T Nguyen, Charlotte S Lo, Michael Fyrsta, et al.
BJU International|November 13, 2010
Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional studyCarmen Mir, Shahrokh F Shariat, Theodorus H van der Kwast, et al.
BJU International|October 27, 2021
Cytoreductive nephrectomy and exposure to sunitinib - a post hoc analysis of the Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer (SURTIME) trialYasmin Abu-Ghanem, Johannes V van Thienen, Christian Blank, et al.
JAMA Oncology|December 14, 2018
Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical TrialAxel Bex, Peter Mulders, Michael Jewett, et al.
Plos One|August 30, 2014
Cell surface profiling using high-throughput flow cytometry: a platform for biomarker discovery and analysis of cellular heterogeneityCraig A Gedye, Ali Hussain, Joshua Paterson, et al.
The Journal of Urology|October 29, 2024
Long-Term Recurrence Risk, Metastatic Potential, and Length of Cystoscopic Surveillance of Low-Grade Nonmuscle-Invasive Bladder CancerEunice Villegas, Katherine Lajkosz, Shayan Din, et al.
Urologic Oncology|January 10, 2017
Quality indicators in the management of bladder cancer: A modified Delphi studySatya R Khare, Armen Aprikian, Peter Black, et al.
Lancet (London, England)|March 13, 2016
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trialNaomi B Haas, Judith Manola, Robert G Uzzo, et al.
European Urology|January 24, 2025
A Call for a Neoadjuvant Kidney Cancer Consortium: Lessons Learned from Other Cancer TypesAxel Bex, Michael Jewett, Bryan Lewis, et al.
European Urology|January 15, 2008
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part IISusanne Krege, Jörg Beyer, Rainer Souchon, et al.
Pageof 7